NCT04085900View on ClinicalTrials.gov

Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City

RecruitingOBSERVATIONAL
Enrollment

40,000

Participants

Timeline

Start Date

April 1, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2027

Conditions
Nasopharyngeal Carcinoma
Interventions
BIOLOGICAL

Blood and saliva

Collect blood and saliva samples from participants

DIAGNOSTIC_TEST

P85-Ab, EBNA1-IgA, VCA-IgA and EBV DNA

Detect P85-Ab, EBNA1-IgA, VCA-IgA for all participants, and detect EBV DNA for all male participants and P85-Ab positive female participants.

DIAGNOSTIC_TEST

Fiberoptic endoscopy and biopsy

Screening participants will refer to fiberoptic endoscopy and biospy

Trial Locations (2)

528403

RECRUITING

Zhongshan People's Hospital, Zhongshan

543002

RECRUITING

Wuzhou Red Cross Hospital, Wuzhou

All Listed Sponsors
collaborator

Wuzhou Red Cross Hospital

OTHER

collaborator

Xiamen University

OTHER

lead

Zhongshan People's Hospital, Guangdong, China

OTHER